Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Targeting Duchenne Muscular Dystrophy

Targeting Duchenne Muscular Dystrophy

FromTargeting the Toughest Diseases


Targeting Duchenne Muscular Dystrophy

FromTargeting the Toughest Diseases

ratings:
Length:
14 minutes
Released:
Dec 19, 2022
Format:
Podcast episode

Description

Before John Killian's toddler son was diagnosed with Duchenne muscular dystrophy (DMD), doctors told parents to simply take their children home and love them. The disease weakens the body's muscles and cognitive functions, which can lead to premature death. John’s son is now college-bound, thanks to the help of medical advancements that target the symptoms of the disease. Geneticist Dr. Alison McVie-Wylie and the research team at Vertex hope to move past only treating the symptoms of DMD by addressing the disease at its root cause. Produced by Bloomberg Media Studios and Vertex Pharmaceuticals. Featured guests:John Killian is the proud father of Sam Killian, who lives with DMD.Mena Scavina is a Neurologist and Clinical Director at Nemours Children's Health and a Clinical Care Team Advisor at Parent Project Muscular Dystrophy.Jon Rey-Hastie is the Co-Founder of Pathfinders Neuromuscular AllianceDr. David Altshuler is the Executive Vice President, Global Research and Chief Scientific Officer at Vertex Pharmaceuticals. Alison McVie-Wylie is a Vice President leading the Duchenne muscular dystrophy research team at Vertex Pharmaceuticals.Read more about Vertex's approach to targeting Duchenne muscular dystrophy. 
Released:
Dec 19, 2022
Format:
Podcast episode

Titles in the series (7)

Targeting the Toughest Diseases looks at some of humanity’s most challenging diseases and how Vertex Pharmaceuticals, a Boston-based biotech company, is using innovative tools, methods, and a unique philosophy to search for treatments and cures. Produced by Bloomberg Media Studios and Vertex Pharmaceuticals.